Approval · Notice of Compliance 31366 · 2023
AREXVY: Notice of Compliance 31366
Issued August 4, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31366
- Date
- August 4, 2023
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AREXVY | 02540207 | Marketed |
Medicinal ingredients
- RESPIRATORY SYNCYTIAL VIRUS PREFUSION F PROTEIN (RSVPREF3) 120 MCG per 0.5ML